Oncology firm Azaya Therapeutics Inc. has announced the formation of a new division that will provide liposomal manufacturing services and chemical testing. The new division will be known as Parexo Labs and is also a CDMO, or contract development and manufacturing organization.
Azaya itself has been busy developing alternative methods for battling cancer through nanotechnology. While still a nascent technology, nanotechnology is currently a hot subject in clinical trials, and companies like Azaya hope to use the method to revolutionize how drugs are delivered to patients in fields like oncology.
It helps in improving female fertility as generic levitra pill well. This quality of healthy, firm and sturdy http://secretworldchronicle.com/books/ cialis generika erection gives a user pleasurable lovemaking time with their partners. These foods replenish the secretworldchronicle.com viagra pill for sale skeletal needs of the body. So, walk about half an hour to decrease about 41% possibility of the risk of ED. cialis in australia The launch of Parexo Labs by Azaya is designed to give the San Antionio-based biotech company the assets necessary to expand further into nanotechnology and other related technologies. A press release recently published by The Wall Street Journal reveals that:
…Parexo Labs leverages Azaya’s twin capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including its proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles. Parexo Labs offers laboratory services that can speed drug development and regulatory progress for pharmaceutical and medical device developers alike…Parexo Labs services cover method development and validation for cytotoxics, as well as raw material testing, stability storage and testing, chemical characterization and other analyses. Parexo also provides customized liposome manufacturing services, based on its proprietary nanoparticle release methodology, to meet customers’ academic or commercial needs.
“Azaya Therapeutics has over ten years of experience in the cytotoxic and nanotechnology arenas, which we are now leveraging with the rollout of Parexo Labs,” Azaya’s CEO and President Mike Dwyer explains.”Through Parexo, we can apply these analytical capabilities and development methodologies to organizations in need of them for their own development programs.” San Antonio-based Azaya, which is a privately held company that was founded in 2003, has held the patent for their PSL (Protein Stabilized Liposome) nanotechnology since 2007 and is working to use this technology in conjunction with liposomes to development new treatments for various cancers.